Hemispherx Biopharma Announces Significant Progress in its Ampligen Pancreatic Cancer Program and Multiple Ampligen+Checkpoint Blockade Immuno-Oncology Programs

by Barry101 | Mar 13, 2019 | Press Release

Hemispherx Provides Quarterly Summary of Rapidly Advancing Oncology Clinical ProgramsOCALA, Fla., March 13, 2019 — Hemispherx Biopharma Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D company focused on...

Hemispherx Biopharma Announces $5.3 Million in Expected Gross Proceeds from Recently Expired Rights Offering

by Barry101 | Mar 6, 2019 | Press Release

OCALA, Fla., March 06, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today...

Hemispherx Announces Dutch Health Inspectorate Approval to Extend the Ampligen Pancreatic Cancer Early Access Program Until March 2020

by Barry101 | Feb 28, 2019 | Press Release

OCALA, Fla., Feb. 28, 2019 — (NYSE American: HEB) – Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today the extension of its Early...

Hemispherx Biopharma Announces Extension of Rights Offering Period to March 5, 2019

by Barry101 | Feb 28, 2019 | Press Release

OCALA, Fla., Feb. 28, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, announced today...

Hemispherx Biopharma Updates the Terms of Previously Announced Rights Offering and Announces Senior Management and Directors All Plan to Participate in the Offering

by Barry101 | Feb 27, 2019 | Press Release

OCALA, Fla., Feb. 27, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced...

Hemispherx Biopharma Announces Commencement of Rights Offering Subscription Period

by Barry101 | Feb 15, 2019 | Press Release

OCALA, Fla., Feb. 15, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, today announced...